Our vision

OUR GOAL: TO HALT THE GLOBAL EPIDEMIC OF CARDIOMETABOLIC DISEASES

According to the WHO (World Health Organization) 2022 report entitled "Invisible numbers", non-communicable diseases such as cardiovascular disease and type 2 diabetes account for over 70% of deaths worldwide. These diseases have multiple causes - social, environmental, commercial and genetic - and affect every region of the globe. Sadly, every year, 17 million people under the age of 70 die prematurely from these diseases.

However, many of these premature deaths could be avoided. The key is to focus on reducing the risk factors associated with these diseases, such as unhealthy diet and a sedentary lifestyle. Fortunately, inexpensive solutions exist for governments and other stakeholders to reduce these modifiable risk factors.

One of the most important risk factors is insulin resistance, which is largely promoted by obesity and a sedentary lifestyle. Insulin resistance is now recognized as a major factor in metabolic syndrome and numerous other diseases, including diabetes and cardiovascular disease. Early detection of insulin resistance, together with dietary and physical activity interventions, is a cost-effective way of preventing the non-communicable diseases associated with metabolic syndrome.
Schéma_Notre_Vision
It's important to note that insulin resistance is not a life sentence. If detected early, sufferers have a window of 10 to 15 years during which they can regain insulin sensitivity. To achieve this, appropriate measures need to be put in place, including lifestyle changes such as a balanced diet and regular physical activity.
Schéma_Notre_Vision_v2
At Innov Biotech, our mission is to combat cardiometabolic diseases by offering the IDIR test. This test offers a reliable, effective and reproducible solution for screening for insulin resistance. By combining the detection of clinical symptoms of insulin resistance with the IDIR test, we enable accurate diagnosis of this condition in the population, as well as prevention of cardiometabolic diseases.
We are committed to advancing cardiovascular and metabolic health, and hope to contribute to reducing the impact of these diseases on a global scale. Join us in our fight against cardiometabolic diseases, and discover how our IDIR test can play a vital role in the prevention and early detection of these conditions.
error:
en_GB